Clinical trials: sponsored by European Organisation for Research and Treatment of Cancer - EORTC
- Lead sponsor (exact) European Organisation for Research and Treatment of Cancer - EORTC
- Has posted results yes
Advanced Hodgkin Lymphoma
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
The main objective of this trial is to assess whether treatment adaptation based on a very early FDG-PET/CT results in improved efficacy while minimizing treatment toxicity in advanced stage Hodgkin Lymphoma (HL) patients treated…
- Trial name
- COBRA (NCT03517137)
- Testing
- Brentuximab Vedotin, Adriamycin, Vinblastine
- Where
- 16 sites in Belgium, Denmark and 5 more
- Volunteers
- 150 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
NSCLC
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
The phase II APPLE trial gives the opportunity to prospectively validate liquid biopsies as a new standard for testing tumor progression compared with conventional radiological procedure in EGFR mutant advanced NSCLC patients.
- Trial name
- APPLE (NCT02856893)
- Testing
- Osimertinib, Gefitinib
- Where
- 23 sites in Belgium, France and 4 more
- Volunteers
- 156 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Astrocytoma, Grade III, Glioblastoma
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
This is a three parallel cohort, open-labeled, non-randomized, multicenter study. All three cohorts will enroll independently.
- Trial name
- STEAM (NCT03224104)
- Testing
- TG02, Radiation Therapy, Temozolomide
- Where
- 10 sites in Austria, France and 3 more
- Volunteers
- 71 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent High Grade Meningioma
Trabectedin for Recurrent Grade II/III Meningioma
The aim of this study is to collect data on activity, toxicity and quality of life of trabectedin therapy in patients with recurrent high-grade meningioma.
- Trial name
- NCT02234050
- Testing
- Trabectedin, Local standard of care
- Where
- 47 sites in Austria, Belgium and 8 more
- Volunteers
- 90 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Newly Diagnosed Glioblastoma
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal.
- Trial name
- MIRAGE (NCT03345095)
- Testing
- Marizomib, Temozolomide, radiotherapy
- Where
- 82 sites in United States, Austria and 10 more
- Volunteers
- 749 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- CATNON (NCT00626990)
- Testing
- temozolomide, DNA methylation analysis, laboratory biomarker analysis
- Where
- 132 sites in United States, Australia and 10 more
- Volunteers
- 751 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Sarcoma
Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
- Trial name
- STRASS (NCT01344018)
- Testing
- therapeutic conventional surgery, 3-dimensional conformal radiation therapy
- Where
- 37 sites in United States, Belgium and 11 more
- Volunteers
- 266 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC